Stockreport

CytoDyn Announces Strong Preclinical Results Using PRO 140 in Human Colon Carcinoma

CYTODYN INC  (CYDY) 
NASDAQ:AMEX Investor Relations: ir.cytodyn.com
PDF CytoDyn will file an IND, along with a proof-of-concept protocol for colon cancer PRO 140 shown effective in inhibiting human colon carcinoma growth VANCOUVER, Washing [Read more]